News Financials About Visit Website Latest News GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress Mar. 28, 2024 9:00 AM ET GeoVax to Present at the 36th Annual Roth Conference Mar. 12, 2024 9:00 AM ET GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Mar. 6, 2024 9:00 AM ET More News Financials About Contact 678-384-7220 Visit Website GeoVax Reports 2023 Year-End Financial Results and Provides Business Update Feb. 29, 2024 4:00 PM ET GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 Feb. 22, 2024 9:00 AM ET GeoVax to Present at the 2024 BIO CEO & Investor Conference Feb. 19, 2024 9:00 AM ET GeoVax Announces Multiple Patent Issuances and Allowances Feb. 13, 2024 9:00 AM ET GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster Feb. 6, 2024 9:00 AM ET GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement Jan. 29, 2024 9:00 AM ET GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology Jan. 8, 2024 9:00 AM ET GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients Jan. 4, 2024 9:00 AM ET GeoVax Announces Issuance of Malaria Vaccine Patent Jan. 3, 2024 9:00 AM ET GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox Dec. 19, 2023 9:00 AM ET GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress Nov. 30, 2023 4:30 PM ET GeoVax to Participate in Upcoming December Investor Events Nov. 29, 2023 9:00 AM ET GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress Nov. 28, 2023 9:00 AM ET Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 Nov. 14, 2023 9:00 AM ET GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update Nov. 8, 2023 4:00 PM ET GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 Oct. 31, 2023 9:00 AM ET GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine Oct. 30, 2023 9:00 AM ET GeoVax to Participate in Upcoming November Investor and Industry Events Oct. 25, 2023 9:00 AM ET GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities Oct. 24, 2023 9:00 AM ET GeoVax Receives Notice of Allowance for Marburg Vaccine Patent Oct. 9, 2023 9:00 AM ET GeoVax Receives Notice of Allowance for HIV Vaccine Patent Oct. 5, 2023 9:00 AM ET GeoVax to Participate in Upcoming October Investor and Industry Events Sep. 27, 2023 9:00 AM ET GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX Suspension Cell Line to Bolster MVA-Based Vaccine Development Sep. 26, 2023 9:00 AM ET GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference Sep. 20, 2023 9:00 AM ET GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients Sep. 19, 2023 9:00 AM ET GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference Sep. 12, 2023 9:00 AM ET GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster Sep. 11, 2023 9:00 AM ET GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference Aug. 31, 2023 9:00 AM ET GeoVax to Present at the Emerging Growth Conference on September 6, 2023 Aug. 29, 2023 9:00 AM ET GeoVax Receives Notice of Allowance for Malaria Vaccine Patent Aug. 28, 2023 9:00 AM ET GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Aug. 10, 2023 9:00 AM ET GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update Aug. 9, 2023 4:00 PM ET GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 Jul. 26, 2023 9:00 AM ET GeoVax Announces Issuance of Ebola Vaccine Patent Jul. 24, 2023 9:00 AM ET GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Jul. 20, 2023 9:00 AM ET GeoVax Presents Gedeptin(R) Clinical Data at the AACR-AHNS Head and Neck Cancer Conference Jul. 10, 2023 9:00 AM ET GeoVax Announces Gedeptin(R) Presentation at the AACR-AHNS Head and Neck Cancer Conference Jun. 28, 2023 9:00 AM ET GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights Jun. 27, 2023 10:15 AM ET GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates May. 31, 2023 9:00 AM ET GeoVax to Participate in Upcoming Industry Meetings May. 25, 2023 9:00 AM ET GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May. 24, 2023 9:00 AM ET GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May. 15, 2023 9:00 AM ET GeoVax Labs to Participate in A.G.P.'s Virtual Healthcare Conference May. 9, 2023 9:00 AM ET GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update May. 4, 2023 4:00 PM ET GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host Apr. 26, 2023 9:00 AM ET GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 Apr. 25, 2023 9:00 AM ET GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses Apr. 17, 2023 9:00 AM ET GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate Apr. 6, 2023 10:00 AM ET GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress Apr. 5, 2023 1:30 PM ET GeoVax to Participate at the World Vaccine Congress with Multiple Presentations Mar. 30, 2023 11:00 AM ET GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update Mar. 23, 2023 4:00 PM ET GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress Mar. 15, 2023 9:00 AM ET GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update Mar. 9, 2023 9:00 AM ET GeoVax to Participate at the 35th Annual Roth Conference Mar. 6, 2023 9:00 AM ET GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections Feb. 27, 2023 9:00 AM ET GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial Feb. 15, 2023 9:00 AM ET GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines Feb. 8, 2023 9:00 AM ET GeoVax Expands Gedeptin Clinical Research for Advanced Head and Neck Cancers Feb. 7, 2023 9:00 AM ET GeoVax to Present at the 2023 BIO CEO & Investor Conference Jan. 26, 2023 9:00 AM ET GeoVax Receives Notice of Allowance for Zika Vaccine Patent Jan. 25, 2023 11:00 AM ET GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 Jan. 4, 2023 9:00 AM ET Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax Dec. 20, 2022 9:00 AM ET GeoVax Appoints Jayne Morgan, M.D., to Its Board of Directors Dec. 7, 2022 4:00 PM ET GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 Nov. 28, 2022 10:15 AM ET GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update Nov. 9, 2022 4:00 PM ET GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 Oct. 26, 2022 9:00 AM ET GeoVax to Present at Vaccines Summit-2022 Oct. 11, 2022 9:00 AM ET GeoVax to Present at Upcoming Investor Conferences Oct. 6, 2022 9:00 AM ET GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 7, 2022 9:00 AM ET GeoVax Announces Addition to Its Board of Directors Sep. 1, 2022 9:00 AM ET GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update Aug. 3, 2022 4:00 PM ET GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization Jul. 28, 2022 9:00 AM ET GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update Jul. 26, 2022 9:00 AM ET GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development Jun. 13, 2022 9:00 AM ET GeoVax to Present at BIO International Convention 2022 Jun. 7, 2022 9:00 AM ET GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May. 25, 2022 1:49 PM ET GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May. 24, 2022 9:00 AM ET GeoVax Announces Upcoming Presentations at Scientific Conferences May. 4, 2022 9:00 AM ET GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update Apr. 27, 2022 4:00 PM ET GeoVax Announces Issuance of Malaria Vaccine Patent Apr. 26, 2022 9:00 AM ET GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update Apr. 19, 2022 9:00 AM ET GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress Apr. 12, 2022 9:00 AM ET GeoVax Announces Issuance of Cancer Vaccine Patent Mar. 22, 2022 9:00 AM ET GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 Mar. 21, 2022 9:00 AM ET GeoVax to Participate in Maxim Group's 2022 Virtual Growth Conference Mar. 16, 2022 9:00 AM ET GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials Mar. 14, 2022 9:00 AM ET Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2 Mar. 10, 2022 9:00 AM ET GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update Mar. 9, 2022 4:00 PM ET GeoVax Announces Key Staff Appointments Mar. 7, 2022 9:00 AM ET GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update Feb. 23, 2022 9:00 AM ET GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 Feb. 22, 2022 1:00 PM ET GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference Feb. 8, 2022 9:00 AM ET GeoVax Announces Closing of $10 Million Private Placement Jan. 20, 2022 9:00 AM ET GeoVax Announces $10 Million Private Placement Jan. 14, 2022 8:47 AM ET GeoVax Retains CATO SMS to Manage Gedeptin Phase 1/2 Clinical Trial Jan. 13, 2022 9:00 AM ET GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer Jan. 11, 2022 9:00 AM ET
GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress Mar. 28, 2024 9:00 AM ET
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Mar. 6, 2024 9:00 AM ET
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 Feb. 22, 2024 9:00 AM ET
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster Feb. 6, 2024 9:00 AM ET
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement Jan. 29, 2024 9:00 AM ET
GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients Jan. 4, 2024 9:00 AM ET
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox Dec. 19, 2023 9:00 AM ET
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 Nov. 14, 2023 9:00 AM ET
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update Nov. 8, 2023 4:00 PM ET
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 Oct. 31, 2023 9:00 AM ET
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine Oct. 30, 2023 9:00 AM ET
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities Oct. 24, 2023 9:00 AM ET
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX Suspension Cell Line to Bolster MVA-Based Vaccine Development Sep. 26, 2023 9:00 AM ET
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference Sep. 20, 2023 9:00 AM ET
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients Sep. 19, 2023 9:00 AM ET
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference Sep. 12, 2023 9:00 AM ET
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster Sep. 11, 2023 9:00 AM ET
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference Aug. 31, 2023 9:00 AM ET
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Aug. 10, 2023 9:00 AM ET
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update Aug. 9, 2023 4:00 PM ET
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 Jul. 26, 2023 9:00 AM ET
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Jul. 20, 2023 9:00 AM ET
GeoVax Presents Gedeptin(R) Clinical Data at the AACR-AHNS Head and Neck Cancer Conference Jul. 10, 2023 9:00 AM ET
GeoVax Announces Gedeptin(R) Presentation at the AACR-AHNS Head and Neck Cancer Conference Jun. 28, 2023 9:00 AM ET
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights Jun. 27, 2023 10:15 AM ET
GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May. 24, 2023 9:00 AM ET
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May. 15, 2023 9:00 AM ET
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update May. 4, 2023 4:00 PM ET
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host Apr. 26, 2023 9:00 AM ET
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 Apr. 25, 2023 9:00 AM ET
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses Apr. 17, 2023 9:00 AM ET
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate Apr. 6, 2023 10:00 AM ET
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress Apr. 5, 2023 1:30 PM ET
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations Mar. 30, 2023 11:00 AM ET
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update Mar. 23, 2023 4:00 PM ET
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress Mar. 15, 2023 9:00 AM ET
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update Mar. 9, 2023 9:00 AM ET
GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections Feb. 27, 2023 9:00 AM ET
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial Feb. 15, 2023 9:00 AM ET
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines Feb. 8, 2023 9:00 AM ET
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 Jan. 4, 2023 9:00 AM ET
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax Dec. 20, 2022 9:00 AM ET
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 Nov. 28, 2022 10:15 AM ET
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update Nov. 9, 2022 4:00 PM ET
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 Oct. 26, 2022 9:00 AM ET
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 7, 2022 9:00 AM ET
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update Aug. 3, 2022 4:00 PM ET
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization Jul. 28, 2022 9:00 AM ET
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update Jul. 26, 2022 9:00 AM ET
GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development Jun. 13, 2022 9:00 AM ET
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May. 25, 2022 1:49 PM ET
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update Apr. 27, 2022 4:00 PM ET
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update Apr. 19, 2022 9:00 AM ET
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress Apr. 12, 2022 9:00 AM ET
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials Mar. 14, 2022 9:00 AM ET
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2 Mar. 10, 2022 9:00 AM ET
GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update Feb. 23, 2022 9:00 AM ET
